UBS has reiterated a neutral stance on Apple, noting that iPhone wait times are relatively flat, with average wait times for the Pro model shorter by about four days year-over-year. Morgan Stanley maintains an equal weight rating on Tesla, expressing a more positive outlook ahead of its earnings report, highlighting the potential of its energy business.
JPMorgan has initiated coverage of Praxis Precision Medicines with an overweight rating and a price target of $700, calling it a unique investment opportunity. StoneX initiated coverage of Toll Brothers with a buy rating, citing the company's strong positioning despite housing market uncertainties.
Other notable initiations include Revolution Medicines and Intuitive Machines, both receiving outperform ratings, with price targets of $226 and an emphasis on the company's solid balance sheet, respectively.
Roth upgraded Avino Silver to buy, indicating significant upside potential, while Goldman Sachs initiated coverage on Elanco and Idexx Laboratories, labeling both as compelling investments in the animal health sector. Piper Sandler initiated coverage of iRhythm with an overweight rating and a price target of $160, suggesting a favorable valuation.
Evercore ISI continues to endorse Nvidia as a buy, countering recent concerns about its performance. Additionally, several companies received upgrades, including EchoStar and Fox, with the latter benefiting from a strategic acquisition. Overall, these analyst calls reflect a diverse range of investment opportunities and risks that investors should consider